Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
:NEU
RESEARCH TOOLSreports
Holding AU:NEU?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.98Last Year’s EPS
0.86Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 27, 2019
|% Change Since: -16.19%
|Next Earnings Date:Feb 27, 2019
Earnings Call Sentiment|Positive
The earnings call highlighted Neuren's strong financial performance, significant cash growth, and successful collaboration with Acadia. Positive trial results for NNZ-2591 and an expanded global reach were significant achievements. However, challenges such as tax liabilities, exchange rate impacts, and share price volatility were noted. Overall, the positive aspects and strategic advancements overshadow the lowlights.Company Guidance
During Neuren's 2023 earnings call, CEO Jonathan Pilcher highlighted several key financial metrics. The company reported a profit of AUD 157 million, fueled by AUD 27 million in royalty income, a USD 59 million milestone payment from DAYBUE's first commercial sale in the U.S., and USD 146 million from an expanded deal with Acadia. Cash reserves increased from AUD 40 million to AUD 229 million without any capital raising. Neuren anticipates royalty income between AUD 61 million and AUD 70 million next year, based on a royalty rate that ranges from 10% to 12%. Additionally, Neuren is expecting USD 50 million in milestone payments as DAYBUE's sales exceed USD 250 million. Neuren's R&D expenses totaled AUD 27 million, with significant efforts directed towards four Phase II trials and preparations for Phase III. Acadia's DAYBUE guidance for 2024 forecasts USD 370 million to USD 420 million in sales, indicating substantial growth from 2023's USD 177 million.Record Profit and Cash Growth
Neuren reported a profit of AUD 157 million, with cash growing from $40 million to $229 million without any capital raising.
Strong Financial Performance from Acadia Partnership
Neuren received $27 million of royalty income, $59 million from DAYBUE's first commercial sale milestone, and $146 million from an expanded deal with Acadia.
Successful DAYBUE Sales
DAYBUE net sales in Q4 reached USD 87 million, hitting the top of Acadia's guidance. Total sales for the partial year were USD 177 million, with 2024 guidance between USD 370 million and USD 420 million.
Expanded Global Reach
The deal with Acadia expanded to include markets outside North America, bringing in USD 100 million upfront, with tiered royalties from mid-teens to low 20s expected once they reach the market.
Positive Phase II Trial Results for NNZ-2591
Outstanding results announced for the Phelan-McDermid syndrome trial, exceeding expectations and showing consistent improvements across multiple efficacy measures.
---
AU:NEU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AU:NEU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Aug 27, 2024 | AU$15.75 | AU$15.34 | -2.60% |
| Feb 29, 2024 | AU$19.15 | AU$19.36 | +1.10% |
| Feb 23, 2023 | AU$7.13 | AU$7.16 | +0.42% |
| Aug 23, 2022 | AU$5.60 | AU$5.48 | -2.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neuren Pharmaceuticals Limited (AU:NEU) report earnings?
Neuren Pharmaceuticals Limited (AU:NEU) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Neuren Pharmaceuticals Limited (AU:NEU) earnings time?
Neuren Pharmaceuticals Limited (AU:NEU) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Neuren Pharmaceuticals Limited stock?
The P/E ratio of Neuren Pharmaceuticals Limited is N/A.
What is AU:NEU EPS forecast?
AU:NEU EPS forecast for the fiscal quarter 2024 (Q4) is 0.98.
---